menu
    • menu
    [{"orgOrder":0,"company":"A.forall","sponsor":"Sagent Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"A.forall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"A.forall \/ Sagent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"A.forall \/ Sagent Pharmaceuticals"},{"orgOrder":0,"company":"A.forall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tromethamine API","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"A.forall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"A.forall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"A.forall \/ Undisclosed"},{"orgOrder":0,"company":"A.forall","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"A.forall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"A.forall \/ A.forall","highestDevelopmentStatusID":"15","companyTruncated":"A.forall \/ A.forall"}]

    Find Clinical Drug Pipeline Developments & Deals by A.forall

    Menu

    A.forall

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            A.forall

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            A.forall

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Provepharm Life Solutions

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            A.forall Expands US Generics Portfolio

                            Details : With the acquisition, A.forall considerably extends its marketed portfolio in the US, including Dihydroergotamine Mesylate, for the treatment of migraine and cluster headaches.

                            Product Name : Dihydroergotamine Mesylate-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 09, 2025

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Provepharm Life Solutions

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            A.forall

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            A.forall

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tromethamine API

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A.forall Launches CGT-Exclusive Tromethamine Injection in US

                            Details : Tromethamine act as a proton acceptor and prevents or corrects acidosis, administered by intravenous infusion, into the ventricular cavity during cardiac arrest.

                            Product Name : THAM Solution

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2025

                            Lead Product(s) : Tromethamine API

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            A.forall

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            A.forall

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Sagent Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A.forall Launches Fifth ANDA and Second “First Cycle” FDA Approval

                            Details : A generic version of Precedex (dexmedetomidine hydrochloride), an alpha2-adrenergic agonist with sedative properties used for short-term intravenous sedation.

                            Product Name : Precedex-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 25, 2024

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Sagent Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth